Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Review Of Byetta Monotherapy Heads Into 2009

This article was originally published in The Pink Sheet Daily

Executive Summary

Amylin/Lilly say FDA is unlikely to complete a review of the diabetes application by the end of the year, as previously anticipated.

You may also be interested in...



FDA's Handling Of Byetta Pancreatitis Risk Could Bode Well For Other Diabetes Drugs

Amylin's Byetta cleared for first-line use without a black box stigma, but sales may still not get a lift.

FDA's Handling Of Byetta Pancreatitis Risk Could Bode Well For Other Diabetes Drugs

Amylin's Byetta cleared for first-line use without a black box stigma, but sales may still not get a lift.

Amylin Submits Once-Weekly Byetta After Shedding 200 Sales Reps

Label with expanded language about thyroid cancer risk is expected.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel